M. Marty

2.3k total citations
4 papers, 83 citations indexed

About

M. Marty is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, M. Marty has authored 4 papers receiving a total of 83 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 1 paper in Molecular Biology and 1 paper in Dermatology. Recurrent topics in M. Marty's work include Cancer Treatment and Pharmacology (2 papers), HER2/EGFR in Cancer Research (1 paper) and Chemotherapy-induced cardiotoxicity and mitigation (1 paper). M. Marty is often cited by papers focused on Cancer Treatment and Pharmacology (2 papers), HER2/EGFR in Cancer Research (1 paper) and Chemotherapy-induced cardiotoxicity and mitigation (1 paper). M. Marty collaborates with scholars based in France. M. Marty's co-authors include Patrice Herait, R. Bugat, D. Khayat, Anne Vincent‐Salomon, A.C. Braud, V. Trillet-Lenoir, F Penault–Llorca, F. Cognetti, L. Mauriac and A. Antón and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Marty

4 papers receiving 81 citations

Peers

M. Marty

ONCOL

CCM

MB

PFM

RNMI

Xiaoyan Kang China

Valentín Cabañas Spain

O. Marco France

Sylvia Hartmann Germany

Michael Pearlman United States

Razeen Mahroof United Kingdom

Jaydutt Bhalshankar Singapore

C. Philippson Belgium

Grzegorz Charliński Poland

Katharina Leitner Austria

Xiaoyan Kang China

M. Marty

62 ×1.3

ONCOL

22 ×0.8

CCM

49 ×2.6

MB

11 ×0.6

PFM

23 ×1.4

RNMI

Citations per year, relative to M. Marty M. Marty (= 1×) peers Xiaoyan Kang

Countries citing papers authored by M. Marty

Since Specialization

Citations

This map shows the geographic impact of M. Marty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Marty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Marty more than expected).

Fields of papers citing papers by M. Marty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Marty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Marty. The network helps show where M. Marty may publish in the future.

Co-authorship network of co-authors of M. Marty

This figure shows the co-authorship network connecting the top 25 collaborators of M. Marty. A scholar is included among the top collaborators of M. Marty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Marty. M. Marty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Penault–Llorca, F, et al.. (2005). Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 764–764. 15 indexed citations

2.

Extra, J.M., F. Cognetti, Ray Snyder, et al.. (2004). Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial. European Journal of Cancer Supplements. 2(3). 125–126. 15 indexed citations

3.

Braud, A.C., et al.. (1999). Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: Report of two patients. Annals of Oncology. 10(10). 1241–1243. 13 indexed citations

4.

Herait, Patrice, et al.. (1992). Early assessment of a new anticancer drug analogue — are the historical comparisons obsolete? The French experience with pirarubicin. European Journal of Cancer. 28(10). 1670–1676. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact